BioCryst Pharmaceuticals, Inc.
BCRX
$6.82
$0.416.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 36.00% | 29.92% | 24.65% | 22.68% | 22.37% |
| Total Other Revenue | -- | -78.50% | -82.57% | -73.84% | -71.75% |
| Total Revenue | 36.00% | 29.92% | 24.65% | 22.68% | 22.37% |
| Cost of Revenue | -13.63% | -11.80% | -13.36% | -11.66% | -16.64% |
| Gross Profit | 129.69% | 131.72% | 146.18% | 204.33% | 949.37% |
| SG&A Expenses | 24.63% | 25.05% | 26.52% | 30.11% | 33.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.36% | 5.52% | 4.32% | 5.68% | 2.61% |
| Operating Income | 97.43% | 66.67% | 50.93% | 33.13% | 33.45% |
| Income Before Tax | 61.56% | 47.08% | 38.89% | 6.52% | 7.43% |
| Income Tax Expenses | 521.61% | -116.95% | -118.74% | -99.87% | -88.66% |
| Earnings from Continuing Operations | 60.77% | 47.61% | 39.88% | 7.81% | 8.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.77% | 47.61% | 39.88% | 7.81% | 8.33% |
| EBIT | 97.43% | 66.67% | 50.93% | 33.13% | 33.45% |
| EBITDA | 100.49% | 68.35% | 52.28% | 34.09% | 34.39% |
| EPS Basic | 63.50% | 51.58% | 43.50% | 11.89% | 11.37% |
| Normalized Basic EPS | 57.85% | 46.44% | 36.91% | 25.59% | 24.08% |
| EPS Diluted | 63.59% | 51.54% | 43.47% | 11.85% | 11.34% |
| Normalized Diluted EPS | 57.85% | 46.44% | 36.91% | 25.59% | 24.08% |
| Average Basic Shares Outstanding | 7.56% | 8.83% | 7.03% | 5.22% | 3.37% |
| Average Diluted Shares Outstanding | 7.56% | 8.83% | 7.03% | 5.22% | 3.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
